583-40-4

Basic information

• Product Name: 8-Mercaptopurine
• Synonyms: 8-MERCAPTOPURINE;7,9-Dihydropurine-8-thione;Purine-8-thiol;1,7-Dihydro-8H-purine-8-thione;Nsc23721;7H-purine-8-thiol
• CAS NO: 583-40-4
• Molecular Formula: C₅H₄N₄S
• Molecular Weight: 152.18
• Product Categories: Purines
• Mol File: 583-40-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 330 °C at 760 mmHg
• Flash Point: 153.4 °C
• Appearance: /
• Density: 1.62 g/cm³
• Vapor Pressure: 0.000171mmHg at 25°C
• Refractive Index: 1.78
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-Mercaptopurine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Mercaptopurine(583-40-4)
• EPA Substance Registry System: 8-Mercaptopurine(583-40-4)

Safety Data

• Hazardous Substances Data: 583-40-4(Hazardous Substances Data)

Usage

General Description

8-Mercaptopurine, also known as 6-MP, is a chemical compound used primarily as a chemotherapy drug for the treatment of various types of cancers and autoimmune diseases. It is a purine analogue that interferes with DNA synthesis, obstructing the growth and multiplication of cancer cells. The drug, often given orally, is metabolized in the body into active derivatives that interfere with nucleic acid biosynthesis, making it effective against both dividing and non-dividing cancer cells. However, its usage often brings about side-effects such as bone marrow suppression, liver toxicity and increased susceptibility to infections. 8-Mercaptopurine’s structure is based on the purine structure found in DNA and RNA.

InChI:InChI=1/C5H4N4S/c10-5-8-3-1-6-2-7-4(3)9-5/h1-2H,(H2,6,7,8,9,10)

Upstream product

• 75-15-0 carbon disulfide 
• 13754-19-3 4,5-pyrimidinediamine 
• 17356-08-0 thiourea 
• 33426-53-8 8-(methylthio)purine 

Downstream Products

• 91808-94-5 7,8-dihydro-thiazolo[3,2-e]purine 
• 7597-61-7 6,7-Dihydro-thiazolo<2.3-f>purin 
• 23658-67-5 8-Methylamino-purin 
• 20296-09-7 8-aminopurine 
• 33426-53-8 8-methylthiopurine 

Relevant articles and documents

HINDERED DISULFIDE DRUG CONJUGATES

The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.

NOVEL VIRAL REPLICATION INHIBITOR

The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one benzimidazole conjugates derivative havin the general formula I. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula and their use as a medicine or to treat or prevent viral infections.